Cencora, Inc.

Cencora's capital structure is highly leveraged, with a debt-to-equity ratio of 3.97, indicating significant reliance on debt financing. The company's liquidity position is strained, as evidenced by a current ratio of 0.92, where current liabilities exceed current assets. Despite holding $1.75 billion in cash and equivalents, the company's net cash position is negative after subtracting total debt of $7.58 billion. Free cash flow for the quarter was -$2.42 billion, driven by a -$2.31 billion operating cash outflow, which reflects challenges in converting revenue into cash. Profitability metrics show mixed performance. Return on equity (ROE) is strong at 29.33%, driven by a relatively high net income of $559.6 million on total equity of $1.91 billion. However, return on assets (ROA) is weak at 0.71%, indicating inefficiency in asset utilization. Gross profit of $3.07 billion on revenue of $85.93 billion yields a gross margin of 3.57%, which is below the industry median for pharmaceutical distributors. Operating income of $760.4 million translates to an operating margin of 0.88%, also below the industry average. The company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. segment is the primary revenue driver, with a broad customer base including acute care hospitals, retail pharmacies, and long-term care facilities. International operations are less detailed in the financials but are described as focusing on pharmaceutical wholesale and global commercialization services. Revenue concentration is heavily weighted toward the U.S., with no specific geographic breakdown provided in the financial snapshot. Growth trajectory is uncertain. Revenue for Q1 2026 was $85.93 billion, up from $81.49 billion in the same period of 2024. However, the outlook for the current fiscal year is constrained by macroeconomic and regulatory headwinds, including the One Big Beautiful Bill Act (OBBBA) and opioid-related litigation. The company's capital expenditure of $119.4 million reflects ongoing investment in infrastructure, but the free cash flow deficit suggests limited capacity for organic growth or M&A. Risk factors are elevated. The company faces high liquidity risk due to negative working capital and negative net cash after debt. Dilution risk is medium, with management signals indicating potential share repurchase activity and a recent filing that mentions dilution or offering risk. The risk assessment also highlights exposure to litigation, regulatory changes, and geopolitical uncertainties, which could impact future earnings and cash flows. Recent events include a $249.5 million impairment charge on goodwill and other intangible assets, reflecting asset valuation pressures. The company also reported a credit of $86.2 million related to litigation and opioid-related expenses, suggesting some resolution of prior liabilities. Management has signaled consideration of an accelerated share repurchase arrangement, which could impact share count and earnings per share.